Sunesis Pharmaceuticals, Inc. announced that on December 16, 2020, Dayton Misfeldt provided notice of resignation from his positions with the company as interim Chief Executive Officer, principal executive officer and principal financial officer, and member of the Board of Directors, effective as of December 31, 2020, in order to pursue another opportunity. Mr. Misfeldt’s resignation was not the result of any disagreement with Sunesis on any matter relating to finances, accounting, operations, practices or policies. Mr. Misfeldt has agreed to continue as a consultant to assist in an orderly transition. Mr. Misfeldt is expected to enter into a consulting agreement, under which Mr. Misfeldt will provide consulting services to through the completion of the previously announced merger with Viracta Therapeutics, Inc. Pursuant to the Consulting Agreement, the options to purchase common stock held by Mr. Misfeldt will continue to vest through the closing of the Merger. In conjunction with Mr. Misfeldt’s resignation, on December 16, 2020, the Board appointed Parvinder S. Hyare, Senior Vice President, Commercial, as interim Chief Executive Officer, effective January 1, 2021. In this role, he will be acting as principal executive officer. Mr. Hyare joined in 2014 as Vice President of Market Access, and has been promoted to SVP, Commercial in 2019. Mr. Hyare has over 20 years of experience in leadership of organizations across global, national, and regional geographies to drive significant success with commercial and development stage products within biotechnology and pharmaceutical markets. Prior to joining Sunesis, Mr. Hyare was Executive Director, Managed Markets & Reimbursement at AMAG Pharmaceuticals, Inc. and previously served as National Sales Director for that company from 2008 until 2014. Prior to AMAG, Mr. Hyare was Region Business Director and also served in various management roles across sales and managed markets for Ortho Biotech a division of Johnson & Johnson from 2000 until 2008. Mr. Hyare began his career at Merck & Co. as a Sales Representative/Vaccine Specialist. Mr. Hyare holds a BS in Business Administration and minor in chemistry from CSU Stanislaus. In addition, on December 16, 2020, the Board appointed Tina Gullotta, Vice President, Finance and principal accounting officer as its principal financial officer, effective January 1, 2021. Ms. Gullotta joined in August 2018 with extensive experience in accounting, finance, and investor relations in the biotech industry. Prior to joining Sunesis, Ms. Gullotta was the Corporate Controller and held various other management positions at Atara Biotherapeutics, Inc. a public immunotherapy company, from February 2014 to January 2018. Prior to joining Atara Biotherapeutics, Inc. Ms. Gullotta held financial management positions in various industries including retail and telecommunications and began her career in the business assurance practice with PricewaterhouseCoopers LLP.